Drawing for BELWAYO

USPTO serial 99446997

BELWAYO

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BELWAYO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Elizabeth K. Rucki

Elizabeth K. Rucki GSK410 Blackwell StreetDurham, NC 27701United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectivesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 18, 2025MAB1ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT—
Dec 18, 2025ABN1ABANDONMENT - EXPRESS MAILED—
Dec 17, 2025EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Oct 16, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 16, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 16, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance